Ahead of ARWR’s phase III SHASTA-3/4 in 3Q26, we have published a new in-depth report on the ARWR/IONS sHTG debate, challenging the view that Ionis is comfortably ahead...
Ahead of VRTX’s phase III RAINIER readout in IgAN (est. mid 2026), povetacicept is currently being viewed as though it is structurally differentiated...
